Akt (also known as protein kinase B/PKB) is a serine/threonine kinase that functions as the central processing hub of the PI3K/Akt pathway, translating extracellular growth factor and nutrient signals into coordinated intracellular responses governing glucose uptake, protein synthesis, cell survival, autophagy suppression, and neuroplasticity. Full activation requires dual phosphorylation at threonine-308 (T308) by PDK1 and serine-473 (S473) by mTORC2, creating a master switch that determines whether cells grow, survive, or die.
Imagine Akt as a factory production manager who needs two keys to start the assembly line β one from the floor supervisor (PDK1) and one from the executive office (mTORC2). When growth hormones or insulin arrive like delivery trucks at the loading dock (cell membrane), they trigger a recruitment process: PI3K generates PIP3 lipids that act like parking spots specifically marked "Akt loading zone." Akt drives to these spots, gets both keys turned simultaneously, and then powers up the entire factory. Once active, this manager walks through the facility shutting down wasteful departments (turning off FOXO's starvation programs, blocking GSK-3Ξ²'s glycogen breakdown, stopping BAD's demolition crew from triggering cell death) while ramping up productive ones (opening GLUT4 glucose delivery doors via AS160, activating mTOR's protein synthesis lines, promoting growth). But if inflammatory alarm bells (TNF-Ξ±, IL-6) sound, security guards block the manager from even reaching the parking spots β the keys never turn, glucose piles up outside, and the factory slides into energy crisis despite adequate fuel supply. This is insulin resistance at the molecular level.
Insulin/growth factor binding β receptor tyrosine kinase activation β IRS-1/2 phosphorylation (on tyrosine residues) β recruitment and activation of PI3K (phosphoinositide 3-kinase) β conversion of PIP2 to PIP3 at plasma membrane β PIP3 recruits Akt via its PH domain β PDK1 (phosphoinositide-dependent kinase 1) phosphorylates Akt at T308 β mTORC2 (mTOR complex 2) phosphorylates Akt at S473 β fully activated Akt dissociates from membrane
Negative regulation: PTEN dephosphorylates PIP3 back to PIP2, removing Akt recruitment signal; PP2A dephosphorylates Akt directly at S473
ΒΆ Downstream Targets and Effects
graph TD
A["Activated Akt<br/>T308+S473 phosphorylated"] --> B[AS160/TBC1D4]
A --> C["GSK-3Ξ²"]
A --> D[FOXO1/3/4]
A --> E[TSC2]
A --> F[BAD]
A --> G[MDM2]
A --> H["IKKΞ±"]
B -->|phosphorylation| B1["GLUT4 translocation<br/>glucose uptake β"]
C -->|inhibitory phosphorylation| C1["Glycogen synthesis β<br/>glycogen breakdown β"]
D -->|"phosphorylation + nuclear export"| D1["Gluconeogenesis β<br/>autophagy β<br/>antioxidant genes β"]
E -->|inhibitory phosphorylation| E1["mTORC1 activation<br/>protein synthesis β<br/>cell growth β"]
F -->|phosphorylation| F1["Apoptosis inhibition<br/>cell survival β"]
G -->|"phosphorylation + activation"| G1["p53 degradation<br/>cell cycle progression"]
H -->|activation| H1["NF-ΞΊB activation<br/>inflammatory responses"]
Specific targets:
-
AS160 (TBC1D4) β Akt phosphorylates at Thr642 β inactivates this GAP protein β allows Rab proteins to remain GTP-loaded β GLUT4 vesicles translocate to membrane β glucose uptake increases 10-40 fold in muscle and adipose
-
GSK-3Ξ² β Akt phosphorylates at Ser9 β inhibits kinase activity β removes brake on glycogen synthase β glycogen synthesis proceeds; also reduces pro-inflammatory signaling
-
FOXO transcription factors β Akt phosphorylates FOXO1 (Thr24, Ser256), FOXO3 (Thr32, Ser253), FOXO4 (Thr28, Ser193) β 14-3-3 proteins bind β FOXO exports from nucleus β blocks transcription of gluconeogenic enzymes (PEPCK, G6Pase), autophagy genes (LC3, Atg12), and pro-apoptotic genes (Bim, FasL)
-
TSC2 β Akt phosphorylates at Thr1462 β disrupts TSC1-TSC2 complex β removes GAP activity toward Rheb β Rheb-GTP accumulates β activates mTORC1 β promotes protein synthesis, lipid synthesis, ribosome biogenesis while blocking autophagy
-
BAD β Akt phosphorylates at Ser136 β sequesters BAD away from mitochondria via 14-3-3 binding β prevents Bcl-2/Bcl-xL inhibition β blocks cytochrome c release β prevents apoptosis
TNF-Ξ±/IL-6 signaling β activates JNK, IKK, PKC isoforms β phosphorylate IRS-1 on serine residues (Ser307, Ser636, Ser1101) β blocks tyrosine phosphorylation β prevents PI3K recruitment β Akt activation fails despite insulin presence β insulin resistance
Chronic inflammation also activates: mTORC1/S6K β feedback phosphorylation of IRS-1 Ser636/639 β further Akt blockade
- Akt1 β ubiquitous; regulates cell growth, survival, angiogenesis; knockout β growth retardation
- Akt2 β enriched in insulin-responsive tissues (muscle, liver, adipose); primary mediator of metabolic insulin actions; knockout β diabetes-like syndrome
- Akt3 β brain-specific; regulates neuronal survival, brain size; knockout β microcephaly
Akt sits at the mechanistic intersection of metabolic disease, neurodegeneration, and inflammation β making it central to understanding cPNI's "selfish systems" framework. When immune activation becomes chronic, the body prioritizes energy allocation to immune cells by deliberately blocking Akt in muscle and liver, creating insulin resistance that ensures glucose availability for leukocytes and acute-phase responses. This is evolutionary logic (survive infection) creating modern pathology (type 2 diabetes, metabolic syndrome).
In metabolic dysfunction: Impaired Akt signaling is the definitive molecular feature of insulin resistance. Even with hyperinsulinemia (insulin levels >15 ΞΌU/mL fasting), Akt fails to activate due to inflammatory serine phosphorylation of IRS-1. Clinically assess via HOMA-IR >2.5, fasting insulin >10 ΞΌU/mL, or 2-hour glucose >140 mg/dL on OGTT. Interventions targeting Akt restoration: reduce systemic inflammation (eliminate LPS-triggering foods, repair gut barrier), activate AMPK (exercise, time-restricted eating), supplement with Akt-independent glucose disposal enhancers like MOTS-c or 12,13-diHOME.
In neurodegeneration: The brain's "type 3 diabetes" paradigm in Alzheimer's disease reflects cerebral insulin resistance where neuronal Akt fails to respond to insulin/IGF-1. This blocks BDNF-mediated survival signaling, impairs glucose metabolism forcing neurons toward alternative fuels, and prevents Akt's normal suppression of GSK-3Ξ² β allowing tau hyperphosphorylation and amyloid accumulation. Cerebrospinal fluid insulin <0.3 ng/mL correlates with cognitive decline. Intranasal insulin trials (40 IU) show modest benefit by bypassing peripheral resistance to restore brain Akt activity.
In cancer: Akt hyperactivation (via PIK3CA mutations, PTEN loss, receptor overexpression) drives uncontrolled growth via mTORC1 and blocks apoptosis via BAD phosphorylation. Up to 50% of cancers have PI3K/Akt pathway mutations. This creates therapeutic paradox β we want Akt active in metabolic tissues but suppressed in malignancies.
The Wingless-Akt sensory sprouting connection: Module 5 and Module 10 material reveals that nutrient scarcity activates Wingless/Wnt β Ror receptor β Akt signaling in sensory neurons, triggering axonal arborization to expand sensory territory and improve nutrient detection. This demonstrates Akt's role beyond metabolism β as a neuroplastic survival response to environmental challenge. Chronic caloric restriction or micronutrient deficiency can inappropriately activate this pathway, contributing to peripheral sensitization and pain amplification.
Intervention leverage points:
- Anti-inflammatory diet to reduce TNF-Ξ±/IL-6 β restore IRS-1 tyrosine phosphorylation
- Resistance training β muscle contraction activates Akt independently of insulin via mechanical stress
- Intermittent fasting β depletes hepatic glycogen β sensitizes Akt pathway when refeeding
- Cold exposure β activates brown adipose tissue Akt via Ξ²3-adrenergic signaling
- Avoid chronic mTORC1 activation (excessive leucine, constant feeding) β prevents S6K-mediated IRS-1 serine phosphorylation
- Three phosphorylation states: inactive (unphosphorylated), partially active (T308 only ~50% activity), fully active (T308 + S473 = 100% activity)
- Half-maximal insulin-stimulated Akt activation occurs at ~2-5 nM insulin; maximal at ~10-20 nM
- In insulin-resistant muscle, Akt T308 phosphorylation reduced by 50-80% despite normal insulin binding
- Akt2 knockout mice develop fasting hyperglycemia (>200 mg/dL) and insulin resistance identical to type 2 diabetes
- Neuronal Akt activation requires lower thresholds than peripheral tissues β explains preferential brain insulin sensitivity
- Exercise-induced Akt activation in muscle is insulin-independent, mediated via calcium/AMPK/reactive oxygen species
- PTEN tumor suppressor (deleted in 30-40% cancers) is the primary negative regulator of Akt via PIP3 dephosphorylation
- Akt phosphorylates >100 substrates; the six core targets (AS160, GSK-3Ξ², FOXO, TSC2, BAD, MDM2) account for most physiological effects
- Metformin improves insulin sensitivity partly by reducing mTORC1-S6K-IRS1 serine phosphorylation, indirectly enhancing Akt activation
- Serum Akt phosphorylation (in platelets or leukocytes) correlates inversely with HOMA-IR; proposed biomarker for insulin resistance severity
- insulin-resistance β central molecular defect is impaired Akt activation due to inflammatory cytokine-mediated IRS-1 serine phosphorylation; systemic manifestation of "selfish immune system"
- PI3K β obligate upstream activator; generates PIP3 second messenger that recruits Akt to membrane via PH domain; PI3K-Akt axis is oncogenic when constitutively active
- IRS β insulin receptor substrate proteins (IRS-1, IRS-2) provide tyrosine-phosphorylated docking sites for PI3K; their serine phosphorylation by inflammatory kinases blocks entire pathway
- GLUT4 β Akt promotes translocation via AS160/TBC1D4 phosphorylation; accounts for 80% of insulin-stimulated glucose uptake in muscle; Akt2-specific effect
- mTOR β Akt activates mTORC1 indirectly via TSC2 inhibition, creating nutrient-sensing switch; mTORC1 feedback inhibits Akt via IRS-1 serine phosphorylation
- FOXO β Akt phosphorylates FOXO1/3/4 causing nuclear export and inactivation; removes transcriptional brake on anabolic processes; blocks autophagy and gluconeogenesis
- TNF-Ξ± β archetypal insulin resistance mediator; activates JNK β IRS-1 Ser307 phosphorylation β blocks Akt; elevated in obesity (>10 pg/mL), metabolic syndrome
- IL-6 β dual role: acutely pro-metabolic via AMPK, chronically anti-Akt via SOCS3 upregulation and sustained IRS-1 serine phosphorylation when >5 pg/mL
- type-2-diabetes β defined by peripheral Akt failure; muscle Akt2 T308 phosphorylation reduced 60-70% in diabetics vs controls; restoration is therapeutic goal
- MOTS-c β mitochondrial-derived peptide activates skeletal muscle Akt independently of insulin receptor, bypassing inflammatory blockade; promising insulin resistance intervention
- skeletal-muscle β primary insulin-responsive tissue; contains 70% of GLUT4 transporters; muscle Akt2 mediates bulk of whole-body glucose disposal
- BDNF β activates neuronal Akt via TrkB receptor β PI3K pathway; promotes dendritic growth, spine formation, synaptic plasticity, neuronal survival; impaired in depression
- apoptosis β Akt is master survival kinase; phosphorylates BAD (Ser136) preventing mitochondrial cytochrome c release; activates MDM2 promoting p53 degradation
- GSK-3Ξ² β Akt phosphorylates at Ser9 causing inhibition; removes brake on glycogen synthase; also suppresses pro-inflammatory NF-ΞΊB and reduces tau phosphorylation
- autophagy β Akt suppresses via dual mechanism: mTORC1 activation (blocks ULK1 complex) and FOXO inhibition (reduces autophagy gene transcription); nutrient abundance signal
- Wingless β Wnt/Wingless signaling intersects Akt pathway via Ror receptors in neurons; nutrient scarcity β Wnt β Akt β sensory axon arborization (Module 5/10 mechanism)
- neuroplasticity β Akt promotes activity-dependent synaptic strengthening via local protein synthesis (mTORC1), CREB phosphorylation, and spine actin remodeling
- mitochondrial-function β Akt regulates mitochondrial biogenesis via PGC-1Ξ± pathway; promotes glucose oxidation; Akt3 specifically enriched in neuronal mitochondria
- chronic-inflammation β creates systemic Akt resistance via TNF-Ξ±/IL-6; evolutionary adaptation (prioritize immune glucose needs) becomes disease (metabolic syndrome, neurodegeneration)
- Alzheimer's disease β brain insulin resistance with 45% reduction in cortical Akt signaling; impairs neuronal glucose metabolism and survival; GSK-3Ξ² hyperactivity promotes tau pathology
- metabolic-flexibility β Akt enables metabolic switching; its activation promotes glucose oxidation while suppressing fat oxidation (via ACC); insulin resistance locks metabolism
- resistance-training β mechanical load activates muscle Akt via integrin-FAK-PI3K and calcium-dependent pathways; insulin-independent route to restore glucose disposal
- AMPK β energetic stress sensor that enhances Akt pathway sensitivity; exercise and metformin activate AMPK β improved insulin-stimulated Akt phosphorylation
- NF-ΞΊB β bidirectional relationship: Akt can activate NF-ΞΊB via IKK phosphorylation; but chronic NF-ΞΊB activation (via TNF-Ξ±) blocks Akt via IRS-1 serine phosphorylation
- BDNF β neurotrophin activates Akt in hippocampal neurons promoting survival and plasticity; exercise increases BDNF β Akt β neurogenesis; impaired in depression and dementia
- Module 1 β Akt as metabolic gatekeeper; evolutionary trade-offs between growth and longevity
- Module 5 β Wingless/Ror/Akt pathway in sensory nerve sprouting under nutrient scarcity
- Module 7 β Akt in skeletal muscle glucose metabolism; insulin resistance mechanisms
- Module 8 β Neuronal Akt in brain insulin signaling, neuroplasticity, and neurodegeneration
- Module 10 β Integration of peripheral metabolic signals (insulin/Akt) with central nervous system function